Search
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Richard J. O’Reilly, MD, was named to the Ninth Annual Giants of Cancer Care®.
Structural biologists at Memorial Sloan Kettering Cancer Center are collaborating with biochemists and cell biologists at The Rockefeller University to study how cells read genetic instructions imprinted on histones, DNA's packaging proteins.
In this Q&A, MSK hematologic oncologist Sergio Giralt, MD, talks about a phase 3 trial of ide-cel CAR T therapy for people with recurrent multiple myeloma and what it may mean for people with this hard-to-treat blood cancer.
The awards are given annually to people in an array of fields in the arts and sciences.
A passion for both science and the humanities has informed the life and career of Dr. Ivan Maillard, who was recently selected to lead the Division of Hematologic Malignancies at MSK.
Gynecologic cancer surgeon Carol Brown featured in Crain's New York Business’ Notable Black Leaders and Executives list.
Scientists have found a protein that empowers prostate tumors to resist hormone therapy.
On Thursday, June 11, at 11:30 AM, 45 high school seniors will participate in the MSK Kids 14th Annual Convocation ceremony. Each year, MSK celebrates our youngest patients (who have all battled cancer or a blood disorder) who are receiving their high school diploma or equivalency.
Very low-dose radiotherapy (VLDRT) is effective for treating grade 3A follicular lymphoma and provides patients with a shorter treatment course and fewer side effects.